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ABSTRACT
Objective The roll- out of the Pfizer- BioNTech BNT162b2 
COVID-19 vaccine has brought many logistical challenges, 
such as the absence of comprehensive stability data 
leading to strict handling instructions during dilution 
and administration. Accidental mishandling therefore 
presents challenging clinical dilemmas, which often led 
vaccine providers to err on the side of caution and discard 
mishandled vials rather than risk administering ineffective 
vaccine. This study aims to answer key questions about 
the vaccine’s stability to allow for a more informed 
decision- making process should a non- conformity occur.
Methods Residual vaccine in freshly used, but 
appropriately stored vials collected from vaccination 
centres in Brighton, UK, were tested after exposure to 
various handling conditions and analysed by dynamic 
light scattering to determine the size of the lipid- mRNA 
nanoparticles, and gel electrophoresis to visualise the 
mRNA integrity and separation from the lipid formulation.
Results Knocking or dropping vaccine samples from 
small heights resulted in lowest levels of instability, 
indicating low risk of compromising clinical efficacy. 
However, repeated drawing and injecting through 23 G 
needles at high speed and, more significantly, shaking 
and vortexing led to progressive increase in the size and 
polydispersity index of the lipid- mRNA nanoparticles, 
coupled with or caused by up to ~50% release of mRNA 
from the lipid formulation. This is thought to impact the 
vaccine’s efficacy due to lack of free mRNA protection and 
cellular internalisation.
Conclusions These results reiterate the importance of 
adhering to the manufacturer’s instructions on handling, 
especially with regard to shaking and exposing the vaccine 
to excessive vibration.
INTRODUCTION
The regulatory approval of COVID-19 
vaccines, including the BNT162b2 COVID-19 
mRNA (Pfizer- BioNTech) vaccine, has 
offered the world a ray of hope to accel-
erate the end of the COVID-19 pandemic. 
However, the huge vaccine roll- out of the 
Pfizer- BioNTech vaccine in the UK has not 
gone without its challenges, mainly due to 
the logistics involved in its distribution and 
storage at very low temperatures. Other 
factors also posed significant hurdles to its 
use; for instance, the strict handling instruc-
tions which were specified as part of the 
conditions of authorisation resulted in the 
need to recruit more healthcare professionals 
(or trained healthcare students) to help with 
the dilution, drawing up and administration 
of the vaccine. This has also caused a degree 
of uncertainty about the potential adverse 
consequences of accidental mishandling of 
the vaccine. Pfizer’s guidelines currently state 
that the vaccine vials should only be inverted 
Strengths and limitations of this study
 ► This translational study answers key questions 
raised in COVID-19 vaccination centres regarding 
the stability of the Pfizer- BioNTech COVID-19 vac-
cine on handling, to inform decision- making process 
should accidental mishandling or non- conformity 
occur.
 ► The close collaboration between healthcare profes-
sionals in vaccination centres and scientists at the 
University of Brighton allowed for timely access to 
residual vaccine, accurate data collection and test-
ing of handling conditions highly relevant to clinical 
practice.
 ► The validity of the results was confirmed through re-
peated testing on at least three separate occasions.
 ► Since vaccine vials were prioritised solely for vac-
cination use during the peak of the pandemic, tests 
were performed on small samples aliquoted into 
plastic tubes (up to 0.3 mL, equivalent to one vac-
cine dose) taken from residual vaccine in used but 
appropriately handled bottles, rather than full six- 
dose glass vials.
 ► The detected instability upon mishandling indicates 
a reduction in the vaccine’s efficacy; however, clin-
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gently 10 times after thawing and dilution with saline, 
and should not be shaken.1 2 Further instructions stated 
that diluted vaccines should not be transported by motor 
vehicles away from the site of dilution, due to possible 
exposure to vibrations,3 suggesting that any vibrational 
stress may destabilise the vaccine or reduce its efficacy. 
Although a follow- up study conducted by Pfizer to mimic 
exposure to vibration showed that diluted vaccine main-
tained its measured quality attributes during ground 
transportation,4 no data have been provided about the 
effect of moderate to vigorous shaking of diluted vaccine, 
the effect of repeated or rapid drawing of the vaccine 
through needles, or the accidental dropping of vials or 
syringes, which particularly led many vaccine providers to 
err on the side of caution and discard precious vaccine. 
Without this information, it is not known whether viable 
vaccine is wasted unnecessarily or whether extra precau-
tions should indeed be taken to minimise loss of efficacy 
due to mishandling.
A successful multidisciplinary collaboration, initiated 
at the start of the UK’s vaccine roll- out, comprising a 
psychologist, pharmacists, a clinical pharmacologist, 
nurses, scientists, immunologists and medical staff from 
University Hospitals Sussex NHS Foundation Trust, 
Brighton and Sussex Medical School, the Primary Care 
Network, Sussex Community Trust and the University 
of Brighton, allowed for stability testing of the Pfizer- 
BioNTech vaccine to answer those key questions. Residual 
vaccine from freshly used but appropriately stored vials 
was tested for its physical stability using two techniques to 
determine (1) signs of aggregation, by measuring the size 
of the vaccine’s mRNA- encapsulating lipid nanoparticles 
by dynamic light scattering, and (2) signs of mRNA degra-
dation or release from the lipid nanoparticles by agarose 
gel electrophoresis. Three different types of handling 
conditions were tested to mimic clinical practice: deter-
mining the effect of shaking and exposure to vibrations, 
dropping the vials from various heights and drawing 
through a 23 G needle repeatedly and at increasing 
speeds. This article therefore provides further details on 
the consequences of vaccine mishandling, to inform the 
decision- making process regarding the integrity of the 




Used but freshly diluted vials (from batches EL7834 
Exp 04/2021, EL8713 Exp 05/2021 and EN1185 
Exp 05/2021) containing any residual volume of the 
COVID-19 Pfizer- BioNTech vaccine after five or six doses 
had been dispensed were obtained from the vaccination 
centres at the Brighton Racecourse and the Royal Sussex 
County Hospital in Brighton, UK. The vials had been 
stored under recommended conditions and tested within 
6 hours of dilution. Apart from the necessary ~10 min car 
journey to the university campus laboratory, the vials were 
not subjected to any additional vibrations. All equipment 
(pipette tips and Eppendorf tubes) used in the handling 
of the vaccine were certified DNase/RNase- free and glass-
ware was rinsed copiously with DNase/RNase- free water 
(Merck Chemicals, Notts, UK) before use. Gloves and 
a face mask were worn throughout the duration of the 
experiments to avoid mRNA degradation due to naturally 
present RNases on the surface of the skin. DNase/RNase- 
free water was also used to reconstitute buffers used in 
electrophoresis experiments. Every experiment was 
repeated on at least three separate occasions to ensure 
that the results were reproducible.
Aliquots (60 or 300 µL) from pooled volumes of 4–10 
vaccine vials (which were pretested to check if they were 
all of similar particle size) were gently pipetted into 
1.5 mL capacity DNase/RNase- free Eppendorf tubes 
(ThermoFisher Scientific, Staffordshire, UK), which were 
then subjected to three main types of handling condi-
tions to mimic different clinical scenarios: (1) samples 
were shaken to varying degrees; by gentle inversion (the 
current recommended practice), flicking or shaking at 
moderate speed by moving up and down 10 times (similar 
to shaking applied when reconstituting injections), 
shaking vigorously (similar to shaking an oral suspen-
sion), or subject to vibration by vortexing on a vortex 
mixer (Fisher Scientific, UK) set at a maximum speed 
for 10 s; (2) samples were knocked over on a bench or 
dropped from various heights (10, 30 or 130 cm) onto a 
bench or laminate flooring; and (3) samples were drawn 
and injected through a 23 G needle up to five times, at 
different speeds (up to 300 µL/s). Controls were used in 
every experiment and were left untreated.
Dynamic light scattering
Approximately ~45 µL from each of the above handled 
samples were transferred to disposable low volume (45 µL) 
polystyrene clear cuvettes (purchased from Malvern 
Panalytical, Worcestershire, UK) without further dilu-
tion, and the apparent hydrodynamic size of the vaccine 
formulation was measured by dynamic light scattering 
at 25°C using a Zetasizer Nano ZS (Malvern Panalytical) 
as described previously.5 6 Three repeat measurements 
(of 13–17 runs each) were performed for each sample. 
Results were statistically analysed by analysis of variance 
(ANOVA) followed by a Dunnett post- test.
Gel electrophoresis
Agarose gel electrophoresis was performed to visualise 
mRNA. Migration of the mRNA band can reveal the type 
of instability that the various handling conditions might 
inflict on the mRNA within the lipid formulation. Ten 
microlitres from each of the above samples was trans-
ferred into separate DNase/RNase- free Eppendorf tubes 
without further dilution, and 2 µL of gel loading buffer 
(containing 0.25% w/v bromophenol blue and 40% w/v 
sucrose, purchased from Merck Chemicals) was added to 
each sample. A 10 µL volume of the final reconstituted 
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mRNA; however, not all the mRNA dose was expected 
to be visible on the gel since only free (uncondensed or 
unencapsulated) mRNA was expected to migrate down 
the gel. To release the full dose of mRNA, for compar-
ison purposes, unhandled 10 µL samples were treated 
with 2 µL of 0.1% v/v Triton X-100 (Merck Chemicals) to 
disrupt the lipid nanoparticles and release the mRNA. An 
RNA ladder (500–9000 bases; New England BioLabs, UK) 
was also used as a reference to verify the size of the mRNA 
in the vaccine.
Control or test samples were loaded onto a 1% w/v 
agarose (Fisher Scientific) gel in tris–acetate–EDTA 
buffer (pH 8.3) prepared in DNase/RNase- free water 
containing 2 µL of GelRed nucleic acid stain (Cambridge 
Biosciences, UK) as described previously.5 7 The gel was 
run at 100 V for 30 min and then visualised under UV 
light using an AlphaImager (Alpha Innotech, UK).
RESULTS
Effect of shaking and vortexing
The effect of shaking and vortexing was tested in order 
to mimic handling conditions during dilution and 
mixing with saline in the clinical setting, and to simulate 
more extreme levels of shaking or exposure to vibration. 
The size measurement and gel electrophoresis results 
Figure 1 (A) Hydrodynamic diameter (left axis) and polydispersity index (right axis) of COVID-19 Pfizer/BioNTech vaccine 
nanoparticles upon subjecting the vaccine to gentle inversion, flicking, shaking mod., shaking vig. or vortexing. Numbers 
above bars are hydrodynamic diameter values (nm). Numbers below the scatter points are polydispersity indices. **Significant 
difference when compared to the control (analysis of variance with Dunnett post- test, p<0.01). Each data point was an average 
of three measurements±SD. (B) Gel electrophoresis of corresponding samples labelled from the graph above showing mRNA 
release from the lipid formulation. The first band in the gel is an RNA ladder, and the last band is vaccine treated with 0.1% 
v/v Triton X-100, representing 100% mRNA release from the formulation. The table under the gel is a semiquantification of the 
band intensity using ImageJ analysis, showing fractional mRNA increase in intensity compared to the control and the % release 
compared to a sample treated with Triton X-100. (C,D) Average size distribution plots by intensity of the corresponding samples 
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are shown in figure 1. In comparison to the untreated 
control, no significant difference was observed in the 
lipid particle size or polydispersity index (a measure of 
heterogeneity or variability in size distribution) when the 
sample was inverted gently or flicked 10 times (although 
a slight increase in average size and polydispersity index 
was observed in the latter sample as shown in figure 1A, 
despite not being significantly different). Particle size 
grew significantly (p<0.01; ANOVA, Dunnett post- test) 
in vigorously shaken and vortexed samples. The poly-
dispersity index also increased significantly (p<0.01) 
in samples that were moderately shaken, vigorously 
shaken and vortexed. It should be noted that despite 
only a slight increase in the average particle size, for 
example, a 6.1 nm increase in the case of the moder-
ately shaken sample compared to the control, the coin-
ciding increase in polydispersity index (from 0.202 to 
0.255) indicated the presence of a small number of 
much larger particles, the presence of which increased 
the average population size. This was evident from the 
intensity size distribution plots (shown in figure 1C,D), 
which showed a reduction in the intensity of the main 
size peak and either the appearance of another larger 
size distribution peak or a widening in the distribution 
of the main peak towards the larger particle size range, 
as opposed to the lower size range, suggesting that the 
polydispersity index increase was due to the presence 
of larger and not smaller particles. In the case of the 
moderately shaken sample (orange line in figure 1D), 
the larger- sized population peaked at around 1000 nm, 
suggesting the presence of a small number of very 
large particles. In the case of the vigorously shaken and 
vortexed samples, larger second peaks or broadening 
and shifting of the original size peak suggested the pres-
ence of an even higher proportion of larger particles, 
indicating a higher degree of aggregation.
Gel electrophoresis (figure 1B) shows the migration of 
free (unencapsulated) mRNA down the gel and the posi-
tion of the band reflects its molecular weight. In compar-
ison to a reference RNA ladder, the size of the vaccine’s 
mRNA appears to be between 3000 and 5000 bases long, 
which matches the expected size of the modified spike 
mRNA protein in the BNT162b2 vaccine, reported to 
be 4284 bases long.8 The samples tested (which were 
the same as those used for size measurement) showed a 
corresponding increase in the mRNA band intensity with 
increasing levels of shaking and vortexing, suggesting 
that more free mRNA has been released from the lipid 
formulation and was available to travel down the gel. 
The increased gel band intensity highly correlated with 
the increase in particle size (R2 value was measured to 
be 0.9954), suggesting that the observed aggregation was 
related to the mRNA release from the lipid nanoparticle 
formulation. It should be noted, however, that no degra-
dation or breakdown of the size of the mRNA was observed 
due to the absence of any smaller molecular weight bands 
or smears underneath the main mRNA band in the tested 
samples. This is thought to be attributed to modifications 
made to the mRNA, to improve its stability to enzymatic 
degradation.8
In order to get an idea of the approximate amount 
of mRNA separation, vaccine samples were treated with 
0.1% v/v Triton X-100 to release the encapsulated mRNA. 
Band intensity analysis using ImageJ (which provides an 
approximate semi- quantitative estimate of band bright-
ness) is shown in the table within figure 1B, suggesting 
that the amount of mRNA release due to Triton X-100 
was around 8.2- fold higher compared with control (which 
equated to ~12.2% of mRNA release from the control 
relative to that released using Triton X-100). This also 
equated to ~2.9- fold and 4.1- fold increases in mRNA 
release in the vigorously shaken and vortexed samples, 
respectively, when compared with the control. This was 
also estimated to be ~35% and~50% of the overall mRNA 
dose, respectively.
Effect of dropping from various heights
Vaccine samples were knocked over on a bench or 
dropped from various heights to mimic accidental drop-
ping during transportation, dilution or administration. 
Size measurement results (figure 2A) showed no signif-
icant difference in the actual size or the polydispersity 
index when compared with the control. However, a slight 
increase in size was observed in all samples, which was 
highest in the sample dropped from a 130 cm height (an 
average increase of 3.1 nm) mirrored by a slight increase 
in polydispersity index, suggesting minor aggregation. 
The size intensity distribution of the samples was also 
comparable to that of the control (data not shown). The 
release of mRNA from the lipid formulation was also 
similar to that of the control, as shown from gel elec-
trophoresis results in figure 2B. Some fluorescence was 
detected just underneath the well, which could be due 
to partial mRNA release from the complex that was not 
fully released to travel down the gel, but remained loosely 
associated with the lipid nanoparticles. This was mostly 
evident in samples dropped from a 30 cm height.
It should be noted that 60 µL sample volumes were used 
in the experiments used for figures 1 and 2; however, 
larger samples of 300 µL were also tested in selected 
samples and showed very similar results (online supple-
mental figure S1 in online data repository).
Effect of repeated drawing and injection through a 23 G 
needle at different speeds
Each Pfizer/BioNtech multidose vaccine contains 
between five and six doses, which means that during 
administration, some of the vaccine volume may be drawn 
up and expelled through a needle multiple times (e.g. 
to adjust the volume in the syringe or expel bubbles). 
Furthermore, the speed at which vaccine is drawn and 
expelled through a needle may also affect the integrity of 
the lipid nanoparticles. To assess whether encapsulated 
mRNA vaccine is damaged during this process, 300 µL 
volume (equivalent to one dose) of vaccine was drawn 
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needle size) once, three or five times, and at different 
speeds, to mimic the number of times doses are removed 
and variation in speed of injection in clinical practice. 
Drawing and releasing the syringe content was counted as 
one injection cycle. Sizing results in figure 3A showed very 
small, mainly insignificant differences. However, particle 
size generally grew progressively with increasing number 
of injections, as well as the speed of injection. Although a 
small increase in particle size and polydispersity index was 
observed in most samples, a significantly larger particle 
size was detected only in the sample injected very quickly 
(delivering the whole 300 µL dose in one second) and 
repeated five times. With regard to polydispersity index, 
a significant difference was observed in the 1 s injection 
(repeated both three and five times). This is reflected by 
a decrease in intensity size peak, and a slight widening 
and rightward shift in the intensity size in figure 3D. This 
observation indicates an increase in particle size and a 
larger distribution of particle sizes.
Gel electrophoresis results (figure 3B) showed a slight 
increase in band intensity, indicating further mRNA 
release from the formulation; however, it was most 
pronounced with increasing the number of injections (ie, 
five injections), in which case up to 2.7- fold increase in 
mRNA release was detected compared with the control 
(this equated to ~31.2% release compared with Triton 
X-100 treatment).
DISCUSSION
This study highlights details that are, to our knowledge, 
not yet available in the literature, regarding the phys-
ical stability of the Pfizer- BioNTech COVID-19 mRNA 
BNT162b2 vaccine. These results are particularly perti-
nent in view of the special precautions which have to be 
observed in handling this first in class mRNA vaccine.
Physical stability
Due to the prioritised vaccine’s clinical use during the 
peak of the pandemic, it was deemed unethical to test 
(and therefore waste) full multidose bottles of vaccine, 
which is why samples from remaining vaccines after the 
doses were removed were tested in smaller volumes (up 
to 300 µL) in plastic tubes, which were comparable to 
single vaccine doses in plastic syringes. Interestingly, the 
results showed that the vaccine’s stability can be compro-
mised when mishandled, mainly by shaking the vaccine 
or exposing it to vibrations, and to a lesser extent, on 
Figure 2 (A) Hydrodynamic diameter (left axis) and polydispersity index (right axis) of COVID-19 Pfizer/BioNTech vaccine 
nanoparticles upon knocking over or dropping from various heights. Numbers above bars are hydrodynamic diameter 
values (nm). Numbers below the scatter points are polydispersity indices. Results were not significantly different from the 
control (analysis of variance with Dunnett post- test). Each data point was an average of three measurements±SD. (B) Gel 
electrophoresis of corresponding samples labelled from the graph above showing mRNA release from the lipid formulation. The 
table under the gel shows semiquantification of the band intensity using ImageJ, showing fractional mRNA increase in intensity 
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repeated injection through a 23 G needle at high speed 
(300 µL/s). Knocking or dropping the vaccine from 
various heights showed minor changes, however they 
were not significantly different from the control. The 
physical instability of the vaccine appears to mainly stem 
from particle aggregation, coupled with or caused by the 
release or separation of the mRNA from the lipid formu-
lation. This is strongly evident in the case of shaken and 
vortexed samples (figure 1) where an extremely high 
correlation between particle size and the amount of 
mRNA release was observed (R2 value=0.9954).
Due to practical reasons, and to ensure that the 
vaccine was collected and tested within 6 hours of dilu-
tion, different vaccine batches were tested on separate 
occasions. It was noted that the size and polydispersity 
index of the untreated controls varied slightly between 
Figure 3 (A) Hydrodynamic diameter (left axis) and polydispersity index (right axis) of COVID-19 Pfizer/ BioNTech vaccine 
nanoparticles upon injecting a 300 μL dose through a 23 G needle over 10, 3, 2 and 1 s, once, three or five times. Numbers 
above bars are hydrodynamic diameter values (nm). Numbers below the scatter points are polydispersity indices. * and ** 
indicate a significant difference when compared to the control (analysis of variance with Dunnett post- test, p<0.05 and p<0.01, 
respectively. Each data point was an average of three measurements±SD. (B) Gel electrophoresis of corresponding samples 
in the graph above showing mRNA release from the lipid formulation. The last band in the gel is vaccine treated with 0.1% v/v 
Triton X-100, representing 100% mRNA release from the formulation. The table under the gel is a semiquantification of the band 
intensity using ImageJ, showing fractional mRNA increase in intensity compared to the control and the % release compared 
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batches, as shown in figures 1–3. This is most probably 
due to batch- to- batch variability, or slight differences in 
handling conditions before obtaining the vials. However, 
reassuringly, repeat experiments performed on batches 
with slightly different starting size showed a very similar 
and proportional increase in particle size and polydisper-
sity index, as well as mRNA release when tested under 
the same conditions. Notably, untreated control samples 
consistently showed around 12% of free mRNA migration 
down the gel, which was detected in every gel electropho-
resis experiment. This could be attributed to the incom-
plete encapsulation efficiency of the mRNA (estimated 
from these experiments to be around 88%), which may 
be deemed within expected and acceptable limits by the 
manufacturer. Comparably, encapsulation efficiency of 
similar lipid nanoparticle formulations, also containing 
the mRNA spike protein, was reported to be around 92%.9
Vaccine efficacy
Although the biological activity of the vaccine’s mRNA 
expression was not tested in this study, it is well recognised 
that naked mRNA that is not complexed or encapsulated 
within its delivery vector is highly unstable in the extra-
cellular environment due to degradation by RNases.10–12 
Although the mRNA used in the Pfizer COVID-19 vaccine 
has been modified to minimise enzymatic degrada-
tion8 (which was consistent with the gel electrophoresis 
results conducted in this study due to the absence of 
degradation bands), the fact that a higher proportion 
of the mRNA dose was released from its delivery vector 
was still concerning. In the absence of a delivery vector, 
free mRNA does not have the ability to diffuse across cell 
membranes due to its large molecular weight (estimated 
to be ~1.5 MDa) and its anionic charge, which is repelled 
by the negative charges of the proteoglycan- coated cell 
membrane.10 13 Since mRNA requires cellular machinery 
to synthesise and express the viral spike protein that 
generates the immune response, the vaccine’s efficacy is 
expected to be reduced if the mRNA is released from its 
formulation. Based on the results obtained, it is therefore 
highly probable that the vaccine loses some of its efficacy 
when mishandled.
Another implication of the observed instability could be 
attributed to the aggregation of the vaccine formulation, 
since large particles may not be internalised into cells by 
endocytosis as efficiently as smaller particles, leading to a 
reduction in the vaccine’s efficacy. A study conducted by 
Moderna Therapeutics14 found that lipid nanoparticles 
encapsulating mRNA vaccine (similar in formulation to 
the Pfizer- BioNTech vaccine) showed best efficacy when 
the particle size was between 75 nm and 95 nm in diameter, 
both in terms of mRNA expression and immunogenicity. 
Larger (up to 140 nm) or smaller (down to 50 nm) particles 
resulted in reduced efficacy.14 Furthermore, nanoparticles 
in the size range 10–100 nm, injected via the intramuscular 
route, can enter the lymphatic system readily and drain to 
lymphoid organs rapidly (within hours of injection), which 
is vital for the vaccine’s efficacy since that permits direct 
access to dendritic cells and uptake and presentation to B 
cells.15 16 Nanoparticles larger than ~200 to 500 nm do not 
enter the lymph nodes as efficiently and take over 24 hours 
to drain into lymph nodes, thereby reducing the efficacy 
and stability of the mRNA in vivo.17
An important observation worth noting is that the insta-
bility stemming from both aggregation and mRNA release 
is progressive in nature, depending on the amount of force 
applied during handling, and significant instability was 
detected even though small sample volumes and plastic 
tubes were used. In figure 1, vigorous shaking resulted 
in higher instability compared with moderate shaking or 
flicking, and in figure 3, repeated and quicker drawing also 
showed increase in size, polydispersity index and mRNA 
release. Minimising the number of handling steps involved 
between dilution and administration to patients is there-
fore desired while reiterating the importance of adhering 
to manufacturer’s handling instructions.
CONCLUSIONS
The results of this study indicate that handling of the Pfizer- 
BioNTech COVID-19 mRNA BNT162b2 vaccine requires 
care and attention, as specified by the manufacturers. 
However, further detail is provided on potential breaches in 
handling which might impact the efficacy of the vaccine in 
a clinical setting. Repeated and rapid drawing up and injec-
tion of the vaccine doses should be minimised. Knocking 
over or dropping vaccine samples from small heights 
showed a low level of physical instability, indicating low risk 
of compromising efficacy; however, it should be noted that 
small volume samples in plastic tubes rather than full multi-
dose glass vials were tested, and biological efficacy has not 
been directly assessed in this study.
The compromise in physical stability seen, particularly 
with shaking or exposing the vaccine to vibrations, endorses 
the need for close supervision of vaccine preparation, 
handling and administration in order to maintain stan-
dards. As the experience of vaccinators increases, adher-
ence to pharmacy- approved standard operating procedures 
continues to be an important control in reducing the risk of 
vaccine degradation.
The desire to minimise wastage balanced against the risk 
of administering ineffective vaccine can create conflict in 
clinical decision making, and our data provide some indi-
cation and reassurance of vaccine stability following very 
minor breaches in clinical use.
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